jRCT2031220441暂停不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 入组人数
- 12
- 主要终点
- Response to treatment at Week 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
入选标准
- •Age 18 years or older.
- •Diagnosis of primary CAD.
- •Hb level <_ 9 g/dL.
- •An absolute neutrophil count >_ 1500 cells/mm3 at screening.
- •Documented results from bone marrow biopsy within 1 year of screening
- •Either have vaccination against Streptococcus pneumoniae, Neisseria meningitidis (Types A, C, W, Y, and B), and Haemophilus influenzae (Type B) within 2 years prior to screening or agree to receive vaccination during screening.
- •Women of childbearing potential (WOCBP), defined as any women who have experienced menarche and who are NOT permanently sterile or postmenopausal, must have a negative pregnancy test at screening and agree to use protocol-defined methods of contraception for the duration of the study and 8 weeks after their last IMP dose.
- •Men must agree to the following for the duration of the study and 8 weeks after their last IMP dose:
- •a. Avoid fathering a child.
- •b. Use protocol-defined methods of contraception.
- •c. Refrain from donating sperm.
- •Willing and able to give written informed consent.
排除标准
- •Have received other anticomplement therapies (approved or investigational) within 5 half-lives of the agent prior to randomization
- •Treatment with rituximab monotherapy within 12 weeks prior to randomization, or rituximab combination therapies (e.g., with bendamustine, fludarabine, other cytotoxic drugs or ibrutinib) within 16 weeks prior to randomization.
- •Use of prohibited medications.
- •Diagnosis of systemic lupus erythematosus or other autoimmune disease with antinuclear antibodies.
- •History of an aggressive lymphoma or presence of a lymphoma requiring therapy.
- •Have received an organ transplant.
- •Cold agglutinin syndrome secondary to Mycoplasma pneumoniae, Epstein-Barr virus or other specific causative infection.
- •HIV or hepatitis C virus detectable by polymerase chain reaction at screening or documented in the patient's medical record.
- •Chronic inactive hepatitis B virus with viral loads > 1000 IU/mL (> 5000 copies/mL) at screening or documented in the patient's medical record. Eligible patients who are chronic active carriers (<_ 1000 IU/mL) must receive prophylactic antiviral treatment (e.g., entecavir, tenofovir, lamivudine) according to local country guidelines.
- •Presence of an active malignant disease within the last 12 months other than skin basal cell carcinoma or in situ carcinoma of the cervix. A low-grade lymphoproliferative bone marrow disorder not requiring therapy by itself is not defined as a malignant disease in this context.
- •A monospecific direct antiglobulin test result of IgG > 1+.
- •Presence or suspicion of liver dysfunction as indicated by elevated ALT > 2.5 x ULN, or direct bilirubin levels > 2 x ULN.
- •Hypersensitivity to pegcetacoplan or to any of the excipients or placebo compounds.
- •Known or suspected hereditary fructose intolerance.
- •Unresolved infection caused by encapsulated bacteria including N. meningitidis, S. pneumoniae and H. influenzae.
- •Presence or suspicion of severe recurrent or chronic infections that, in the opinion of the investigator, increase the patient's risk by participating in the study.
- •Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening period.
- •If breastfeeding, is unwilling to discontinue for the duration of study and for at least 8 weeks after the final IMP dose.
- •Inability to cooperate with study procedures.
- •Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition that may jeopardize the patient's wellbeing, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient unsuitable for this study.
- •Protected adults (guardianship, trusteeship) who are unable to express their consent and persons under court protection.
结局指标
主要结局
Response to treatment at Week 24
时间窗: Week 24
Response is defined as: - An increase in hemoglobin (Hb) of ≥ 1.5 g/dL from Baseline or Hb normalization at Week 16; AND - Maintenance of this effect from Week 16 to Week 24; AND - The absence of PRBC transfusions (between Week 5 and Week 24).
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisErosive esophagitisEUCTR2005-001187-31-LTTAP Pharmaceutical Products Inc.1,950
进行中（未招募）
1 期
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and Ustekinumab and the Results of Changing Strength or Frequency of Brodalumab in People with Moderate to Severe Plaque Psoriasis: AMAGINE-3Moderate to severe plaque psoriasisMedDRA version: 14.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-000667-24-GRAmgen Inc.1,800
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisErosive esophagitisEUCTR2005-001188-70-LVTAP Pharmaceutical Products Inc.1,950
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia SyndromeFamilial Chylomicronemia SyndromeMedDRA version: 24.1Level: LLTClassification code 10085051Term: Familial chylomicronemia syndromeSystem Organ Class: 100000004850EUCTR2021-003680-10-IEArrowhead Pharmaceuticals, Inc.60
进行中（未招募）
不适用
Phase III CDK in refractory Cchronic lymphocytic leukemia (CLL)MedDRA version: 14.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2011-005186-20-LVMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.466